<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00970892</url>
  </required_header>
  <id_info>
    <org_study_id>B.30.2.ANK.0.20.05.04</org_study_id>
    <nct_id>NCT00970892</nct_id>
  </id_info>
  <brief_title>VKORC1 and CYP2C9 Gene Polymorphisms and Warfarin Management</brief_title>
  <official_title>Evaluation of VKORC1 and Cytochrome P450 CYP2C9 Gene Polymorphisms and Management of Warfarin Dose Using Pharmacogenetic Data</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ankara University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ankara University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to use pharmacogenetic information in clinical practise which may&#xD;
      lead to rapid, efficient, and safe warfarin dosing in this observational prospective study.&#xD;
      In this context, the investigators plan to develop an algorithm for estimating the&#xD;
      appropriate warfarin dose that is based on both clinical and genetic data from the Turkish&#xD;
      study population. This study is unique not only investigating clinical factors, demographic&#xD;
      variables, CYP2C9, and VKORC1 gene variations which contribute to the variability among&#xD;
      patients in dose requirements for warfarin but also including thrombogenic single nucleotide&#xD;
      polymorphisms (SNP) in the same patient population. Thus, warfarin would be a good example by&#xD;
      being the first cardiovascular drug for pharmacogenetic guided &quot;personalized medicine&quot;&#xD;
      applications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Long-term anticoagulation therapy with warfarin is recommended for patients with atrial&#xD;
      fibrillation/flutter (AF), left atrial thrombus, deep vein thrombosis (DVT), pulmonary&#xD;
      thromboembolism (PE), mechanical heart valve replacement, cardiomyopathy, and ischemic&#xD;
      stroke. Warfarin, a coumarin derivative, produces an anticoagulant effect by interfering with&#xD;
      the vitamin K 2,3 epoxide reductase (VKOR) enzyme and Î³-carboxylation of vitamin K-dependent&#xD;
      clotting factors such as II, VII, IX, and X. However, management of warfarin therapy is&#xD;
      complicated with interindividual differences in drug response, delayed onset of action,&#xD;
      difficulty with reversal and a narrow therapeutic window leading to increased risk of&#xD;
      life-threatening hemorrhagic adverse events or thromboembolism. Furthermore, in order to&#xD;
      determine safe and effective loading dose during the early phase of therapy and maintenance&#xD;
      doses require frequent laboratory monitoring and adjustments to compensate for changes in&#xD;
      patients' age, body size, vitamin K intake through diet, disease state, comorbidities,&#xD;
      concomitant use of other medications, and patient-specific genetic factors.&#xD;
&#xD;
      Poor anticoagulant control may cause fatal complications such as thromboembolism with&#xD;
      undertreatment or bleeding with excessive anticoagulation. Indeed, the risk of major bleeding&#xD;
      in patients on warfarin is between 1% and 5% per year. Identifying the optimal therapeutic&#xD;
      range and managing the dose of therapy to achieve the maximal time in therapeutic range are&#xD;
      two of the most important determinants of therapeutic effectiveness and of reducing&#xD;
      hemorrhagic risk. Currently, there have been substantial efforts to improve the safety of&#xD;
      warfarin anticoagulation therapy. Recent warfarin pharmacogenetic studies have largely&#xD;
      focused on two candidate genes: CYP2C9, responsible for warfarin metabolism, and VKORC1,&#xD;
      which encodes vitamin K epoxide reductase, the site of warfarin action. Current evidence is&#xD;
      clear that polymorphisms in either CYP2C9 or VKORC1 affect warfarin sensitivity.&#xD;
&#xD;
      We aimed to use pharmacogenetic information in clinical practise which may lead to rapid,&#xD;
      efficient, and safe warfarin dosing in this observational prospective study. In this context,&#xD;
      we plan to develop an algorithm for estimating the appropriate warfarin dose that is based on&#xD;
      both clinical and genetic data from the Turkish study population. This study is unique not&#xD;
      only investigating clinical factors, demographic variables, CYP2C9, and VKORC1 gene&#xD;
      variations which contribute to the variability among patients in dose requirements for&#xD;
      warfarin but also including thrombogenic single nucleotide polymorphisms (SNP) in the same&#xD;
      patient population. Thus, warfarin would be a good example by being the first cardiovascular&#xD;
      drug for pharmacogenetic guided &quot;personalized medicine&quot; applications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2009</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Anticipated">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Warfarin related complications including bleeding and thromboembolism</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximal time in international normalized ratio (INR) therapeutic range and deviation from target INR levels</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Cardiac Thrombus</condition>
  <condition>Deep Vein Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <condition>Heart Valve Replacement (Mechanical or Biological With AF)</condition>
  <condition>Cardiomyopathy (Ischemic or Dilated)</condition>
  <condition>Peripheral Vascular Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Warfarin dose titration</intervention_name>
    <description>Dosage</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who require warfarin for at least 6 months under care of cardiovascular surgery,&#xD;
        cardiology and pulmonary disease.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients who require warfarin for at least 6 months with the indications listed below:&#xD;
&#xD;
          -  Permanent Atrial Fibrillation/Flutter&#xD;
&#xD;
          -  Left atrial or ventricular thrombus&#xD;
&#xD;
          -  Deep Vein Thrombosis&#xD;
&#xD;
          -  Pulmonary Embolism&#xD;
&#xD;
          -  Heart Valve Replacement (Mechanical or Biological With AF)&#xD;
&#xD;
          -  Cardiomyopathy (Ischemic or Dilated)&#xD;
&#xD;
          -  Peripheral Vascular Disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of GI bleeding or peptic ulcer disease&#xD;
&#xD;
          -  Significant liver disease, active hepatitis or chronic HBV/HCV infection&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Chronic diarrhea or malabsorption syndrome&#xD;
&#xD;
          -  Viral or bacterial infection prior to enrollment&#xD;
&#xD;
          -  Active or previous infective endocarditis&#xD;
&#xD;
          -  Hospital stay &gt; 30 days as a result of septicemia, mediastinitis or pneumonia&#xD;
&#xD;
          -  Cardiac cachexia&#xD;
&#xD;
          -  Morbid obesity&#xD;
&#xD;
          -  Expected pregnancy, pregnancy or lactation&#xD;
&#xD;
          -  Psychiatric disease&#xD;
&#xD;
          -  Malignancy with Life expectancy less than 1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nejat Akar, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ankara University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>RUCHAN A AKAR, Assoc. Prof.</last_name>
    <phone>+905336460684</phone>
    <email>akarruchan@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>SERKAN DURDU</last_name>
    <phone>+905336373535</phone>
    <email>serkandurdu@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ankara University Medical Faculty, Department of Cardiovascular Surgery and Pulmonary Disease</name>
      <address>
        <city>Ankara</city>
        <zip>06340</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>RUCHAN AKAR, Assoc. Prof.</last_name>
      <phone>+905336424994</phone>
      <email>akarruchan@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>SERKAN DURDU</last_name>
      <phone>+905336373535</phone>
      <email>serkandurdu@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>HILAL OZDAG, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>RUCHAN A AKAR, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ALTAY GUVENIR, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>ISMAIL SAVAS, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>SERKAN DURDU, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GUNSELI CUBUKCUOGLU DENIZ, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>UMIT OZYURDA, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>HAKAN GURDAL, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>GOKHAN H ILK, Assoc. Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>FILIZ CETINKAYA, BSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>September 2009</verification_date>
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 3, 2009</study_first_posted>
  <last_update_submitted>September 2, 2009</last_update_submitted>
  <last_update_submitted_qc>September 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2009</last_update_posted>
  <responsible_party>
    <name_title>NEJAT AKAR, Prof.</name_title>
    <organization>Ankara University</organization>
  </responsible_party>
  <keyword>Anticoagulation</keyword>
  <keyword>warfarin</keyword>
  <keyword>VKORC1</keyword>
  <keyword>CYP2C9</keyword>
  <keyword>thromboembolism</keyword>
  <keyword>pharmacogenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
    <mesh_term>Peripheral Vascular Diseases</mesh_term>
    <mesh_term>Peripheral Arterial Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

